Acceleron Pharma (XLRN) PT Raised to $79 at Oppenheimer Amid Strong Sotatercept Results
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell raised the price target on Acceleron Pharma (NASDAQ: XLRN) to $79.00 (from $57.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
